Chemed (CHE) Aandelenoverzicht
Chemed Corporation biedt hospice- en palliatieve zorgdiensten aan patiënten via een netwerk van artsen, gediplomeerde verpleegkundigen, thuiszorgassistenten, maatschappelijk werkers, geestelijken en vrijwilligers, voornamelijk in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 4/6 |
| Toekomstige groei | 1/6 |
| Prestaties in het verleden | 3/6 |
| Financiële gezondheid | 3/6 |
| Dividenden | 0/6 |
CHE Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Chemed Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$534.79 |
| 52 Week Hoogtepunt | US$551.68 |
| 52 Week Laag | US$365.21 |
| Bèta | 0.52 |
| 1 maand verandering | 14.83% |
| 3 maanden verandering | 26.68% |
| 1 Jaar Verandering | 29.71% |
| 3 jaar verandering | 3.67% |
| 5 jaar verandering | 13.87% |
| Verandering sinds IPO | 4,627.43% |
Recent nieuws en updates
Narratiefupdate • Jul 29
CHE: Buybacks And Activist Pressure Will Shape Margins And Measured Returns
Analysts have lifted their price target fair value for Chemed from $474 to $501.50, citing updated assumptions on revenue growth, profit margins and future P/E that result in a higher overall valuation. What’s in the News for Chemed From April 1, 2026 to June 30, 2026, Chemed repurchased 210,000 shares for US$89.8 million, representing 1.59% of its shares, and has now completed the repurchase of 12,570,646 shares for US$2.91b under the buyback first announced on February 22, 2011.Narratiefupdate • Jul 13
CHE: Share Repurchases And Steady Margins Will Support Measured Future Returns
Analysts have modestly raised their price target for Chemed to $474.0 from $446.5. This change reflects updated views on fair value, profit margins, and the P/E multiple they consider appropriate for the stock. What’s in the News for Chemed Chemed Corporation (NYSE: CHE) was removed from the Russell Small Cap Comp Growth Benchmark, according to index constituent change disclosures.
Narratiefupdate • Jun 29
CHE: Strong Q1 Results And Buybacks Support Balanced Future Return Potential
Analysts have revised their price target on Chemed to $500 from $580, reflecting updated assumptions for slightly higher discount rates, revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for Chemed Chemed reported Q1 revenue of $657.5 million, which was 1.6% higher year over year and 1.2% above analyst expectations, according to recent earnings coverage.Recent updates
Narratiefupdate • Jul 29
CHE: Buybacks And Activist Pressure Will Shape Margins And Measured Returns
Analysts have lifted their price target fair value for Chemed from $474 to $501.50, citing updated assumptions on revenue growth, profit margins and future P/E that result in a higher overall valuation. What’s in the News for Chemed From April 1, 2026 to June 30, 2026, Chemed repurchased 210,000 shares for US$89.8 million, representing 1.59% of its shares, and has now completed the repurchase of 12,570,646 shares for US$2.91b under the buyback first announced on February 22, 2011.Narratiefupdate • Jul 13
CHE: Share Repurchases And Steady Margins Will Support Measured Future Returns
Analysts have modestly raised their price target for Chemed to $474.0 from $446.5. This change reflects updated views on fair value, profit margins, and the P/E multiple they consider appropriate for the stock. What’s in the News for Chemed Chemed Corporation (NYSE: CHE) was removed from the Russell Small Cap Comp Growth Benchmark, according to index constituent change disclosures.Narratiefupdate • Jun 29
CHE: Strong Q1 Results And Buybacks Support Balanced Future Return Potential
Analysts have revised their price target on Chemed to $500 from $580, reflecting updated assumptions for slightly higher discount rates, revenue growth, profit margins, and a lower future P/E multiple. What’s in the News for Chemed Chemed reported Q1 revenue of $657.5 million, which was 1.6% higher year over year and 1.2% above analyst expectations, according to recent earnings coverage.Narratiefupdate • Jun 15
CHE: Share Repurchases And Stable Margins Will Support Balanced Future Returns
Analysts have kept their Chemed price target essentially unchanged at about $446.50, with only minimal tweaks to underlying assumptions such as revenue growth, profit margin, and future P/E to reflect updated modeling rather than a shift in overall outlook. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.Narratiefupdate • Jun 01
CHE: Ongoing Buybacks And Stable Margins Will Support Balanced Future Returns
Analysts have nudged their price target on Chemed higher to $446.50 from $443, reflecting updated assumptions around slightly stronger revenue growth, a modestly higher discount rate, stable profit margins, and a lower future P/E multiple. What's in the News Chemed reported that from January 1, 2026 to March 31, 2026, it repurchased 500,000 shares, representing 3.65% of its stock, for US$197.7 million under its ongoing buyback program.Narratiefupdate • Apr 27
CHE: Ongoing Buybacks And Earnings Guidance Will Support Balanced Future Returns
Analysts now see Chemed’s fair value holding at $443, with updated assumptions for revenue growth of 6.52%, a profit margin of 12.54%, and a future P/E of 15.49x shaping their refreshed price target rationale. What's in the News From January 1, 2026 to March 31, 2026, Chemed repurchased 500,000 shares for $197.7 million, representing 3.65% of its shares under the long running buyback program announced in February 2011 (Key Developments).Narratiefupdate • Apr 10
CHE: Expanded Buybacks And Earnings Guidance Will Support Stronger Future Returns
Analysts have kept their price target for Chemed steady at $443. This reflects updated assumptions around slightly different revenue growth, profit margin and future P/E inputs that do not materially change their overall valuation view.Narratiefupdate • Mar 27
CHE: Expanded Buybacks And Higher Margins Will Support Stronger Future Returns
Analysts have maintained Chemed's price target at $443, citing updated assumptions for profit margin and forward P/E as key factors behind the reaffirmed view. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, with projected earnings per diluted share in a range of $23.25 to $24.25, excluding certain non cash items such as stock option expenses, tax benefits from stock option exercises, litigation costs and other discrete items (corporate guidance).Narratiefupdate • Mar 10
CHE: Revised Outlook And Ongoing Buybacks Will Shape Balanced Future Returns
Analysts have revised their price target on Chemed to $443.00 from $555.50, reflecting updated views on revenue growth, profit margins, and the P/E multiple they consider appropriate for the stock. What's in the News Chemed issued consolidated earnings guidance for full-year 2026, projecting earnings per diluted share, excluding specified non cash and discrete items, in a range of $23.25 to $24.25 (company guidance).Nieuw narratief • Feb 27
Repositioned Hospice Mix And Aging Demographics Will Support Stronger Long Term Performance
Catalysts About Chemed Chemed operates VITAS Healthcare, a large hospice provider, and Roto-Rooter, a national plumbing and water restoration service business. What are the underlying business or industry changes driving this perspective?Narratiefupdate • Feb 24
CHE: Stable Margins And Expanded Buybacks Will Support Future Upside
Analysts maintained Chemed's price target at $555.50, citing unchanged views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News On February 13, 2026, Chemed increased its equity buyback authorization by US$300 million to a total of US$3.05 billion under its existing repurchase program (Key Developments).Narratiefupdate • Feb 10
CHE: Stable Margins And Consistent Assumptions Will Support Future Upside
Analysts have maintained their fair value estimate for Chemed at US$555.50 per share, with only small adjustments to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, resulting in a marginally updated price target narrative. Valuation Changes Fair Value: Kept unchanged at US$555.50 per share, indicating no revision to the central valuation output.Narratiefupdate • Jan 23
CHE: Share Buybacks And Margin Outlook Will Support Future Upside
Analysts now see Chemed's fair value at US$555.50, down from US$582.25. This reflects updated views on the discount rate, revenue growth, profit margin and future P/E assumptions.Analyse-artikel • Jan 16
Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...Analyse-artikel • Oct 31
Analysts Are Updating Their Chemed Corporation (NYSE:CHE) Estimates After Its Third-Quarter Results
It's been a good week for Chemed Corporation ( NYSE:CHE ) shareholders, because the company has just released its...Analyse-artikel • Oct 24
Chemed Corporation (NYSE:CHE) Shares Could Be 38% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Chemed fair value estimate is US$707 Chemed is estimated to be...Seeking Alpha • Oct 06
Chemed Corp: Genius Of The Model Lies In Its Corporate Strategy
Summary Chemed Corp's unconventional structure is masterfully managed with a disciplined focus on operational excellence and shareholder-friendly capital allocation. The company's primary competitive advantage is its brand, a powerful intangible asset cultivated over nearly a century of reliable service and effective marketing. Chemed has constructed a uniquely durable enterprise built to create shareholder value for the long term. Read the full article on Seeking AlphaNarratiefupdate • Sep 03
New Florida CON Sites Will Advance Home-Based And Hospice Care
Chemed’s modest price target increase to $582.25 reflects stable sentiment, as core metrics like future P/E and revenue growth remain virtually unchanged. What's in the News Increased equity buyback authorization by $300 million, bringing total to $2.75 billion.Rendement voor aandeelhouders
| CHE | US Healthcare | US Markt | |
|---|---|---|---|
| 7D | 6.3% | 0.2% | 0.5% |
| 1Y | 29.7% | 45.0% | 16.5% |
Rendement versus industrie: CHE presteerde slechter dan de US Healthcare -sector, die het afgelopen jaar een rendement van 45 % opleverde.
Rendement versus markt: CHE overtrof de US markt, die het afgelopen jaar een rendement opleverde van 16.5 %.
Prijsvolatiliteit
| CHE volatility | |
|---|---|
| CHE Average Weekly Movement | 3.2% |
| Healthcare Industry Average Movement | 7.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiele aandelenkoers: CHE heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 3% ) van CHE is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1970 | 15,811 | Kevin McNamara | www.chemed.com |
Chemed Corporation levert diensten op het gebied van hospice en palliatieve zorg aan patiënten via een netwerk van artsen, verpleegkundigen, thuiszorgmedewerkers, maatschappelijk werkers, geestelijken en vrijwilligers, voornamelijk in de Verenigde Staten. Het bedrijf opereert via twee segmenten: VITAS en Roto-Rooter segmenten. Het bedrijf biedt loodgieterswerk, afvoerreiniging, uitgraving, waterherstel en andere aanverwante diensten aan particuliere en commerciële klanten via eigen vestigingen, onafhankelijke aannemers en franchisenemers.
Chemed Corporation Samenvatting
| CHE fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$7.13b |
| Inkomsten(TTM) | US$274.99m |
| Inkomsten(TTM) | US$2.60b |
25.7x
Koers/Winstverhouding2.7x
P/S-verhoudingIs CHE overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| CHE resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$2.60b |
| Kosten van inkomsten | US$1.74b |
| Brutowinst | US$859.31m |
| Overige uitgaven | US$584.32m |
| Inkomsten | US$274.99m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 20.80 |
| Brutomarge | 33.11% |
| Nettowinstmarge | 10.60% |
| Schuld/Eigen Vermogen Verhouding | 16.9% |
Hoe presteerde CHE op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
0.4%
Huidig dividendrendement6%
UitbetalingsratioBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/30 17:59 |
| Aandelenkoers aan het einde van de dag | 2026/07/30 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Chemed Corporation wordt gevolgd door 10 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Adam Feinstein | Barclays |
| Joanna Sylvia Gajuk | BofA Global Research |
| Peter Martin | Citizens JMP Securities, LLC |